Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tranzyme’s first product shows safety in phase I study
TZP-101 is a selective ghrelin receptor agonist with potent gastroprokinetic properties that represents the first in its class to enter into a clinical trial. The trial was an
TZP-101 is a selective ghrelin receptor agonist with potent gastroprokinetic properties that represents the first in its class to enter into a clinical trial. The trial was an
Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive enzymes normally produced by the pancreas which leads to malnutrition, impaired growth and shortened life expectancy. EPI can result
The collaboration combines Oxford Genome Sciences’ (OGeS) ability to discover novel targets for oncology with Medarex’s expertise in the development of fully human antibody therapeutics. The companies will
The two-year agreement will support intensive laboratory work by a team of research scientists at MD Anderson, who will focus on the novel synthesis and molecular modeling of
The ruling means that the publishing of the private investors’ details or any further contact with them is now prohibited by law, and that anybody who found to
Cymbalta is already approved in the US for the treatment of major depressive disorder and the management of diabetic peripheral neuropathic pain, both in adults. Lilly is also
The in-licensed technology may enable small interfering RNAs – or siRNAs, the molecules that mediate RNAi – to be targeted with an engineered monoclonal antibody to tumors and
The companies aim to create novel, localized treatments that stop tumor re-growth after surgery through the direct application of a combined biomaterial/anticancer therapeutic at the site of tumor
Aradigm’s liposomal ciprofloxacin is an aerosolized formulation of this proven anti-infective drug that was designed to increase the drug’s residence time in the lung and prolong its anti-infective
Merck will acquire 100% of the equity of GlycoFi in an all cash transaction valued at approximately $400 million. GlycoFi is a privately held biotechnology company focused in